

Pharmacy Policy

Kevzara (sarilumab)

Policy Number: 9.151

Version Number: 2.1

Version Effective Date: 3/1/2022

Product Applicability All Plan+ Products

Well Sense Health Plan

New Hampshire Medicaid

Boston Medical Center HealthNet Plan

MassHealth - MCO

MassHealth - ACO

Qualified Health Plans/ConnectorCare/Employer Choice Direct

Senior Care Options

Note: Disclaimer and audit information is located at the end of this document.

Prior Authorization Policy

Products Affected:

- Kevzara (sarilumab)

The Plan may authorize coverage of the above products for members meeting the following criteria:

Covered Use	All FDA approved indications not otherwise excluded
Exclusion Criteria	None
Required Medical Information	<ol style="list-style-type: none"> 1. Diagnosis of Rheumatoid Arthritis (RA); AND <ol style="list-style-type: none"> a. Documentation* showing the member has had an inadequate response or adverse reaction to TWO of the following or a contraindication to ALL: <ol style="list-style-type: none"> i. Enbrel ii. Humira iii. Rinvoq iv. Xeljanz/XR [Note: A trial of either or both Xeljanz products (Xeljanz and Xeljanz

* Plan refers to Boston Medical Center Health Plan, Inc. and its affiliates and subsidiaries offering health coverage plans to enrolled members. The Plan operates in Massachusetts under the trade name Boston Medical Center HealthNet Plan and in other states under the trade name Well Sense Health Plan.

	<p>XR) collectively counts as ONE product v. Actemra subcutaneous.</p> <p>* Documentation may include, but is not limited to, chart notes, prescription claims records, and/or prescription receipts</p>
Age Restrictions	18 years of age or older
Prescriber Restriction	RA: Prescribed by or in consultation with a rheumatologist.
Coverage Duration	Initial: 3 months Reauthorization: 12 months
Other criteria	<p>Reauthorization:</p> <ol style="list-style-type: none"> 1. Initial criteria are met; AND 2. Member's clinical condition has improved or stabilized

Applicable Coding:

None

Clinical Background Information and References

1. Fraenkel L, Bathon J, England, B et al. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. *Arthritis & Rheumatology*. 2021 Jan;71(1):1-16.
2. Kevzara™ injection [prescribing information]. Bridgewater, NJ: Regeneron/Sanofi Genzyme. Accessed July 2021.

Original Approval Date	Original Effective Date	Policy Owner	Approved by
5/24/2021	7/1/2021	Pharmacy Services	Pharmacy & Therapeutics (P&T) Committee

Policy Revisions History

Review Date	Summary of Revisions	Revision Effective Date	Approved by
-------------	----------------------	-------------------------	-------------

* Plan refers to Boston Medical Center Health Plan, Inc. and its affiliates and subsidiaries offering health coverage plans to enrolled members. The Plan operates in Massachusetts under the trade name Boston Medical Center HealthNet Plan and in other states under the trade name Well Sense Health Plan.

Policy Revisions History

5/24/2021	Policy created	7/1/2021	P&T Committee
8/12/2021	P&T Annual Review: Removal of non-biologic DMARD for RA to align with ICCV policy guidelines (per guidelines member will have already trialed these); Minor language updates to	1/1/2022	P&T Committee
1/20/2022	Updated policy to realign with ESI ICCV policy	3/1/2022	P&T Committee

Next Review Date

8/2022

Other Applicable Policies

Reference to Applicable Laws and Regulations, If Any

Disclaimer Information

Medical Policies are the Plan's guidelines for determining the medical necessity of certain services or supplies for purposes of determining coverage. These Policies may also describe when a service or supply is considered experimental or investigational, or cosmetic. In making coverage decisions, the Plan uses these guidelines and other Plan Policies, as well as the Member's benefit document, and when appropriate, coordinates with the Member's health care Providers to consider the individual Member's health care needs.

Plan Policies are developed in accordance with applicable state and federal laws and regulations, and accrediting organization standards (including NCQA). Medical Policies are also developed, as appropriate, with consideration of the medical necessity definitions in various Plan products, review of current literature, consultation with practicing Providers in the Plan's service area who are medical experts in the particular field, and adherence to FDA and other government agency policies. Applicable state or federal mandates, as well as the Member's benefit document, take precedence over these guidelines. Policies are reviewed and updated on an annual basis, or more frequently as needed. Treating providers are solely responsible for the medical advice and treatment of Members.

The use of this Policy is neither a guarantee of payment nor a final prediction of how a specific claim(s) will be adjudicated. Reimbursement is based on many factors, including member eligibility and benefits on the date of service; medical necessity; utilization management guidelines (when applicable); coordination of benefits; adherence with applicable Plan policies and procedures; clinical coding criteria; claim editing logic; and the applicable Plan – Provider agreement.

* Plan refers to Boston Medical Center Health Plan, Inc. and its affiliates and subsidiaries offering health coverage plans to enrolled members. The Plan operates in Massachusetts under the trade name Boston Medical Center HealthNet Plan and in other states under the trade name Well Sense Health Plan.